Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	661.82	607.52	667.24	579.78	520.4
Revenue Growth (YoY)	8.94%	-8.95%	15.09%	11.41%	32.50%
Cost of Revenue	77.91	83.78	87.22	75.06	52.46
Gross Profit	583.91	523.74	580.02	504.71	467.94
Selling, General & Admin	335.78	336.36	377.22	304.76	200.68
Research & Development	108.8	91.59	74.55	90.47	75.96
Operating Expenses	522.56	510.34	534.4	425.22	292.34
Operating Income	61.36	13.4	45.61	79.5	175.6
Interest Expense	-	-2.42	-7.07	-23.42	-23.75
Interest & Investment Income	-	-	-	10.22	14.35
Other Non Operating Income (Expenses)	16.2	10.45	21.68	-	-
EBT Excluding Unusual Items	77.55	21.44	60.22	66.3	166.2
Gain (Loss) on Sale of Investments	0.01	-	0.01	0.35	4.35
Asset Writedown	-	-20.19	-	-	-
Other Unusual Items	6.11	1.52	0.51	6.53	-1.9
Pretax Income	97.87	2.77	60.74	73.18	168.65
Income Tax Expense	24.01	1.45	0.03	19.75	41.7
Net Income	73.87	1.32	60.71	53.42	126.95
Net Income to Common	73.87	1.32	60.71	53.42	126.95
Net Income Growth	5512.84%	-97.83%	13.64%	-57.92%	12.29%
Shares Outstanding (Basic)	55	55	54	53	53
Shares Outstanding (Diluted)	56	56	62	54	54
Shares Change (YoY)	0.81%	-10.01%	13.47%	1.24%	-0.24%
EPS (Basic)	1.34	0.02	1.13	1.01	2.41
EPS (Diluted)	1.32	0.02	1.04	0.98	2.36
EPS Growth	6500.00%	-98.08%	6.32%	-58.48%	12.38%
Free Cash Flow	171.23	110.53	116.41	125.08	134.71
Free Cash Flow Per Share	3.06	1.99	1.89	2.30	2.51
Gross Margin	88.23%	86.21%	86.93%	87.05%	89.92%
Operating Margin	9.27%	2.21%	6.84%	13.71%	33.74%
Profit Margin	11.16%	0.22%	9.10%	9.21%	24.39%
Free Cash Flow Margin	25.87%	18.19%	17.45%	21.57%	25.89%
EBITDA	141.77	98.26	131.16	112.09	193.74
EBITDA Margin	21.42%	16.17%	19.66%	19.33%	37.23%
D&A For EBITDA	80.41	84.86	85.54	32.6	18.14
EBIT	61.36	13.4	45.61	79.5	175.6
EBIT Margin	9.27%	2.21%	6.84%	13.71%	33.74%
Effective Tax Rate	24.53%	52.47%	0.05%	26.99%	24.73%
Revenue as Reported	661.82	607.52	667.24	579.78	520.4

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q